Cortexyme (NASDAQ:CRTX) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell?

Cortexyme, Inc. (NASDAQ:CRTX) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.96 and traded as high as $3.77. Cortexyme shares last traded at $3.67, with a volume of 241,694 shares traded.

Cortexyme Price Performance

The firm has a market capitalization of $110.35 million, a PE ratio of -1.23 and a beta of 1.40. The firm has a fifty day moving average price of $2.62 and a 200 day moving average price of $1.98.

About Cortexyme

Cortexyme, Inc is a clinical-stage biotechnology company focused on the development of treatments for Alzheimer’s disease and other chronic conditions associated with bacterial proteases. The company’s research centers on targeting virulence factors produced by the oral pathogen Porphyromonas gingivalis, an organism increasingly implicated in neurodegeneration. By inhibiting the activity of gingipains—proteolytic enzymes secreted by P. gingivalis—Cortexyme aims to reduce inflammation and tissue damage in the brain and other organs.

The company’s lead product candidate, atuzaginstat (COR388), is a small-molecule inhibitor designed to cross the blood–brain barrier and neutralize gingipain activity.